Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly is presented as the clear winner over Novo Nordisk following their Q2 results, with Lilly’s GLP-1 franchise outperforming and shares rising after earnings while Novo extended losses over two years. On weight-loss products, Zepbound revenue hit $4.9B (+46% YoY) versus Wegovy at about $3B (+1% YoY), and tirzepatide’s weight loss efficacy (20.2% vs. 13.7% for semaglutide over 72 weeks) is cited as a key driver. The article argues Lilly’s pipeline and non-diabetes assets (e.g., Verzenio, Taltz, Kisunla, Jaypirca) are stronger, concluding Lilly is the better buy despite higher valuation (32.7x vs. Novo at 13.8x).

Analysis

The market implication is not just “LLY wins, NVO loses” but that obesity is becoming a scale-and-execution business, not a pure science premium. If Lilly keeps converting efficacy into prescription momentum, the economics compound across manufacturing utilization, sales leverage, and bargaining power with payers; Novo’s weaker cadence risks a slower reset in investor expectations, especially because a large share of the bear case is now about share loss rather than category growth. That tends to compress multiples faster on the laggard than it expands on the leader.

Second-order effects favor the broader obesity supply chain more than either name alone: contract manufacturers, fill-finish capacity, and API/pen-device suppliers should remain bottleneck beneficiaries if demand keeps outrunning supply. The real vulnerability for both stocks is that the category may shift from “best drug wins” to “who can reliably deliver and defend reimbursement”; if that happens, any supply normalization or payer pushback could cap upside within 1-3 months even if clinical data stay favorable. Beyond 6-18 months, oral/next-gen convenience and real-world persistence will matter more than headline efficacy.

The contrarian miss is valuation asymmetry: Lilly is being rewarded for quality, but at a high multiple it has less room for error if growth decelerates or a later-stage readout disappoints. Novo is discounted as if the competitive gap is permanent, yet a manufacturing fix, better access, or a cleaner oral launch could trigger a sharp mean reversion. In other words, the trade is cleaner on relative fundamentals than on absolute upside; the better risk/reward may be a pair rather than an outright long.

Key Decisions for Investors

• Long LLY / short NVO as a 1-3 month relative-value pair; favor the name with operating leverage and pipeline breadth, but size modestly because the spread is already consensus-heavy.
• If not already in, avoid chasing LLY after strength; wait for a pullback or for the next prescription/supply data print to confirm that momentum is persisting beyond the earnings reaction.
• Use NVO as a tactical short only if the next monthly prescription trend or guidance commentary fails to show acceleration; otherwise the stock is vulnerable to a sharp relief rally if supply/reimbursement improves.
• Watch the obesity supply-chain beneficiaries rather than the headline names for a lower-beta expression; any confirmation of continued shortages supports CMOs and device/logistics capacity names over the next 6-12 months.
• Set a falsifier on LLY relative outperformance: if the next quarter shows slower GLP-1 volume growth or margin pressure from capacity expansion, trim the pair quickly because the premium multiple leaves little room for execution misses.